Strontium for Bone Health: Evidence, Strontium Ranelate, and Safety

Table of Contents

  1. Overview
  2. Biological Functions
  3. Dietary Sources
  4. Deficiency
  5. Recommended Intake
  6. Supplementation & Forms
  7. Toxicity & Upper Limit
  8. Special Considerations
  9. Key Research Papers
  10. Connections
  11. Featured Videos

1. Overview

Strontium (chemical symbol Sr, atomic number 38) is a soft, silvery metal that sits directly below calcium in the periodic table. Because it is a divalent cation with a similar size and charge to calcium (Ca2+), the human body cannot fully tell the two apart: it absorbs strontium through the same intestinal pathways, carries it in the blood, and deposits roughly 99% of body strontium in bone and teeth, exactly where it puts calcium. A healthy adult carries only about 300–350 mg of strontium in total — a tiny amount compared with the roughly 1,000–1,200 g of calcium in the skeleton.

This page is about stable (non-radioactive) strontium and its relationship to bone. That distinction matters enormously, because the word “strontium” is also attached to a notorious radioactive isotope, strontium-90 (Sr-90), a product of nuclear fission and atmospheric weapons-test fallout. Sr-90 is a bone-seeking carcinogen: it follows the same calcium-mimic route into the skeleton, where its radiation can damage bone marrow and raise the risk of leukemia and bone cancer. The natural, stable strontium found in food, water, and supplements is a completely different thing — it is not radioactive and does not emit ionizing radiation. The rest of this article concerns only stable strontium; Sr-90 is mentioned only to prevent confusion.

Interest in stable strontium for bone health comes from one main source: a prescription osteoporosis medicine called strontium ranelate (brands Protelos and Osseor), which was approved in Europe in 2004 and showed reduced fracture risk in postmenopausal women. That drug was never approved by the U.S. Food and Drug Administration (FDA), and it was later restricted and then discontinued because of safety concerns. Separately, over-the-counter (OTC) supplements containing strontium citrate are marketed for bones, but they are a different chemical salt with much weaker evidence. Understanding strontium honestly means keeping these three things — the element, the European drug, and the OTC supplement — clearly separate.

Why strontium is talked about at all

Strontium is not a vitamin or an essential mineral, and most clinicians never think about it. It enters health conversations almost entirely through osteoporosis: because it concentrates in bone and, at high doses, changes how bone is built and broken down, it can influence fracture risk and bone-density measurements. As the sections below explain, those effects are real but come with important caveats — including a measurement artifact that makes strontium look better on bone scans than it truly is.

Back to Table of Contents

2. Biological Functions

Strontium has no established essential biological function in humans. Unlike iron, zinc, iodine, or calcium, it is not a required cofactor for any enzyme, hormone, or structural protein, and no human metabolic pathway depends on it. The body tolerates and stores strontium simply because its chemistry is so close to calcium’s — not because it needs it. For that reason, the headings below describe what strontium does at the doses found in medicines and supplements, rather than a physiological “role” the body cannot do without.

Behaving like calcium in bone

Bone is constantly remodeled: cells called osteoclasts break down old bone (resorption), and cells called osteoblasts build new bone (formation). Strontium ions slot into the mineral lattice of bone in place of some calcium ions, and they accumulate especially in newly formed bone. At ordinary dietary levels this substitution is trivial. At the much higher doses used in strontium ranelate, laboratory and animal studies show that strontium can shift the balance of remodeling.

The proposed “dual action”

The most-discussed property of strontium ranelate is its claimed dual action on bone: stimulating osteoblasts to build more bone while reducing osteoclast activity so that less bone is broken down. In cell and animal models this dual effect is well documented and is thought to involve the calcium-sensing receptor and signaling pathways such as OPG/RANKL that govern osteoclast formation (Marie, 2006). If true in people, it would make strontium unusual, because most osteoporosis drugs either slow resorption (bisphosphonates, denosumab) or stimulate formation (teriparatide), but not both.

In humans, however, the “dual action” story is genuinely debated. Critics point out that markers of bone formation rise only modestly in patients, and that much of the apparent benefit on bone-density scans is a measurement artifact (see Section 7) rather than proof of vigorous new bone. So while strontium clearly influences bone biology at pharmacologic doses, the precise mechanism — and how much of the clinical benefit it explains — remains uncertain rather than settled.

Back to Table of Contents

3. Dietary Sources

Stable strontium is widespread in the environment and is present in the ordinary diet, though always in small amounts. Because plants take it up from soil and animals concentrate it in bone, strontium turns up across the food supply roughly in parallel with calcium. Typical total dietary intake is only a few milligrams per day — commonly estimated in the range of about 1–5 mg/day, with most surveys clustering near 2–4 mg/day, depending heavily on diet and local geology.

Common food and water sources

Why geology matters

Because so much dietary strontium comes through soil and water, intake can vary several-fold between regions for reasons that have nothing to do with what someone chooses to eat. This natural variability is one reason strontium has never been given a recommended intake: there is no “deficiency” to correct, and ordinary diets already supply far more than any biological process requires (which, as Section 4 explains, is effectively zero). The milligram-per-day amounts from food are also orders of magnitude smaller than the hundreds of milligrams in strontium supplements or the ~680 mg of elemental strontium delivered by a daily 2-gram dose of strontium ranelate.

Back to Table of Contents

4. Deficiency

There is no recognized strontium deficiency in humans. Because strontium is not an essential nutrient, the body has no requirement for it, and no disease or syndrome results from low strontium intake. People living in areas with strontium-poor water and food are not known to suffer any strontium-specific health problem. This is the central honest point of the page: strontium is interesting for what it does at high (pharmacologic) doses, not for any consequence of having too little.

How this differs from true essential minerals

With genuinely essential minerals — iron, iodine, zinc, calcium — inadequate intake produces a defined deficiency state (anemia, goiter, impaired immunity, poor bone mineralization). Researchers establish a requirement precisely by observing what goes wrong when intake falls and what restores normal function. No such deficiency picture has ever been documented for strontium, so there is nothing for a “requirement” to be based on. Claims that people are “strontium deficient” and need to supplement are not supported by mainstream nutrition science.

The grain of truth marketers stretch

Supplement marketing sometimes implies that low strontium weakens bones and that topping it up is therefore protective. The kernel of fact is that strontium can affect bone at high doses — but that is a pharmacological effect, like a drug, not the correction of a nutritional shortfall. Framing strontium as a nutrient the body is short of misrepresents the evidence. Anyone concerned about bone health is far better served by ensuring adequate calcium, vitamin D, vitamin K2, and protein — nutrients with real requirements — than by trying to fix a strontium “deficiency” that does not exist.

Back to Table of Contents

5. Recommended Intake

There is no Recommended Dietary Allowance (RDA), Adequate Intake (AI), or other official intake value for stable strontium, and there is no Tolerable Upper Intake Level (UL) set by nutrition authorities such as the U.S. National Academies. This follows directly from the fact that strontium is not essential: agencies set reference intakes only for nutrients the body actually requires. The few milligrams per day supplied by an ordinary diet are neither a target to hit nor a number anyone needs to track.

Drug and supplement doses are a separate matter

The doses that produce strontium’s bone effects are not “intakes” in the nutritional sense; they are pharmacologic doses, and they dwarf dietary amounts:

Why “more” is not automatically “better”

Because there is no established requirement and no defined safe upper limit for nutritional strontium, dosing supplements is essentially self-experimentation with a drug-like substance, without the safety monitoring that accompanies a prescription. Higher strontium does not straightforwardly mean stronger bone — very high strontium can actually impair bone mineralization (Section 7), and apparent gains on bone-density scans are inflated by a measurement artifact (also Section 7). For genuinely essential bone nutrients, by contrast, well-defined intake targets exist precisely because their safety and benefit have been characterized.

Back to Table of Contents

6. Supplementation & Forms

Strontium reaches people in two very different ways — as a prescription medicine that exists only outside the United States, and as an OTC dietary supplement. These are not interchangeable, and conflating them is the single most common source of confusion.

Strontium ranelate (prescription — Europe only)

Strontium ranelate (Protelos/Osseor) was approved in the European Union in 2004 for postmenopausal osteoporosis. Its evidence base is two large randomized controlled trials (RCTs):

The drug was never FDA-approved in the United States, so it has never been legally available there as a medicine. As discussed in Section 8, European regulators later restricted its use and the manufacturer discontinued it.

Strontium citrate and other OTC salts

The strontium sold over the counter is usually strontium citrate, and sometimes strontium chloride, lactate, or gluconate. These are different chemical compounds from the ranelate salt studied in SOTI and TROPOS. A key honesty problem in this market is that supplement marketing frequently implies the ranelate trial results apply to citrate — but that has not been established. There are no large fracture-outcome RCTs for strontium citrate comparable to SOTI/TROPOS; the evidence for citrate is weak and largely indirect (chemical similarity, small studies, surrogate markers such as bone-density readings that are themselves distorted by the strontium artifact).

Practical points if strontium is being considered

Back to Table of Contents

7. Toxicity & Upper Limit

Stable strontium is much less acutely toxic than many trace metals, but it is far from harmless at the doses used in medicines and supplements. There is no official nutritional Tolerable Upper Intake Level for strontium, so the safety picture comes from the prescription drug’s clinical record and from studies of high-dose exposure.

Impaired bone mineralization (“strontium rickets”)

Paradoxically, the same mineral promoted for bones can harm bone when intake is very high — especially against a background of low calcium intake or in growing children. Excess strontium can interfere with the normal deposition of calcium and phosphate in the bone matrix, producing a mineralization defect resembling rickets or osteomalacia (soft, poorly mineralized bone). This was described decades ago as “strontium rickets” in animal studies and high-exposure settings (Storey, 1961) and is one reason high-dose strontium is inappropriate for children and for people with poor calcium and vitamin D status.

The DXA measurement artifact — bone density looks better than it is

This is a crucial and underappreciated caveat. Bone mineral density (BMD) is usually measured by dual-energy X-ray absorptiometry (DXA), which infers density from how much X-ray the bone absorbs. Strontium has a higher atomic number than calcium (38 versus 20) and absorbs X-rays much more strongly per atom. When strontium replaces some calcium in bone, the bone blocks more X-rays, and the DXA machine reports a falsely high BMD. Analyses of the strontium ranelate trials concluded that a large fraction of the measured BMD “increase” is this artifact rather than real new bone (Blake and colleagues, 2005). In other words, the impressive bone-density gains often quoted for strontium overstate the true skeletal benefit and must be interpreted and adjusted with great caution — a scan number alone is not trustworthy evidence that strontium has strengthened a bone.

Cardiovascular and clotting risk; DRESS

The most serious human safety signals come from strontium ranelate (covered in detail in Section 8): an increased risk of heart attack (myocardial infarction) and venous thromboembolism (VTE) — blood clots in the legs or lungs — and a rare but severe drug-hypersensitivity reaction called DRESS syndrome (drug rash with eosinophilia and systemic symptoms). These concerns drove the European restrictions and the drug’s withdrawal from the market.

Interference with calcium and laboratory tests

At high doses strontium competes with calcium for absorption, so it can reduce calcium uptake if the two are taken together. High strontium can also affect certain laboratory bone assessments. These are additional reasons to treat hundreds-of-milligrams strontium dosing as a drug-like intervention rather than a casual supplement.

Back to Table of Contents

8. Special Considerations

Strontium ranelate’s rise and fall in Europe

Strontium ranelate illustrates how a drug with proven fracture benefit can still be withdrawn once its harms become clear. After approval in 2004 on the strength of SOTI and TROPOS, post-marketing data and pooled analyses revealed an excess of cardiovascular events — particularly myocardial infarction — and venous blood clots, alongside cases of the serious skin reaction DRESS. In 2013–2014 the European Medicines Agency (EMA) sharply restricted the drug: it was limited to severe osteoporosis in patients who could not use other treatments, contraindicated in people with a history of heart disease, stroke, peripheral arterial disease, uncontrolled high blood pressure, or clotting disorders, and made subject to regular cardiovascular monitoring. Commercially, the medicine was effectively discontinued by its manufacturer around 2017. The practical bottom line for readers in the United States is simple: strontium ranelate is not approved or available there, and even in Europe it is no longer a routine option.

Don’t assume the supplement inherits the drug’s benefits — or escapes its risks

Two opposite errors are common. The first is assuming OTC strontium citrate works as well as ranelate — it has no comparable fracture-outcome trials, so that benefit is unproven. The second is assuming the supplement is automatically safe because it is sold without a prescription — but it still delivers hundreds of milligrams of the same element, and the toxicity concerns (mineralization defects at very high doses, calcium interference, and uncertainty about cardiovascular safety) have never been ruled out for citrate by the kind of large safety studies done for the drug. Honest framing means acknowledging both the weakness of the benefit evidence and the unresolved safety questions for the supplement.

Who should be especially cautious

What actually builds strong bones

Whatever one concludes about strontium, it is at best an adjunct, not a foundation. The well-established pillars of bone health are adequate calcium and vitamin D, vitamin K2 (which helps direct calcium into bone), sufficient dietary protein, and regular weight-bearing and resistance exercise, along with not smoking and limiting heavy alcohol use. For diagnosed osteoporosis, medicines with strong U.S. evidence and approval — bisphosphonates, denosumab, and bone-building agents — are the mainstays. Anyone weighing strontium for bone health should discuss it with a clinician who can weigh the cardiovascular and clotting risks against the modest and uncertain benefit, and who can interpret bone-density scans in light of the strontium artifact.

Back to Table of Contents

9. Key Research Papers

  1. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis (SOTI). New England Journal of Medicine. 2004;350(5):459–468. doi:10.1056/NEJMoa022436
  2. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: TROPOS study. The Journal of Clinical Endocrinology & Metabolism. 2005;90(5):2816–2822. doi:10.1210/jc.2004-1774
  3. Reginster JY, Bruyère O, Sawicki A, et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone. 2009;45(6):1059–1064. doi:10.1016/j.bone.2009.08.004
  4. O’Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database of Systematic Reviews. 2006;(4):CD005326. doi:10.1002/14651858.CD005326.pub2
  5. Marie PJ. Strontium ranelate: a physiological approach for optimizing bone formation and resorption. Bone. 2006;38(2 Suppl 1):S10–S14. doi:10.1016/j.bone.2005.07.029
  6. Blake GM, Fogelman I. Long-term effect of strontium ranelate treatment on BMD. Journal of Bone and Mineral Research. 2005;20(11):1901–1904. doi:10.1359/jbmr.050810
  7. Abrahamsen B, Grove EL, Vestergaard P. Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporosis International. 2014;25(2):757–762. doi:10.1007/s00198-013-2469-4
  8. Cacoub P, Descamps V, Meyer O, et al. Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate. Osteoporosis International. 2013;24(5):1751–1757. doi:10.1007/s00198-013-2265-1
  9. Storey E. Strontium “rickets”: bone, calcium and strontium changes. Australasian Annals of Medicine. 1961;10(3):213–222. doi:10.1111/imj.1961.10.3.213
  10. European Medicines Agency (EMA). Protelos/Osseor (strontium ranelate): recommendation to restrict use following review of cardiovascular safety (PRAC, 2013–2014). European Medicines Agency — Protelos/Osseor referral
  11. MedlinePlus (U.S. National Library of Medicine). Strontium — consumer drug and supplement information. medlineplus.gov — Strontium
  12. National Institute for Health and Care Excellence (NICE). Osteoporosis: assessing the risk of fragility fracture and management of osteoporotic fractures. nice.org.uk — Osteoporosis guidance

Back to Table of Contents

Connections

Back to Table of Contents